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PTV 
volume 
cm3 
Conformity 
Index 
Heterogeneity 
Index 
D25% cc Gradient 
Index 
HD MMLC Diff 
% 
HD MMLC HD MMLC Diff 
% 
HD MMLC 
2.20 1.38 1.44 4.46 0.18 0.18 53.30 67.70 21.27 6.14 7.27 
4.10 1.30 1.33 2.05 0.21 0.22 102.98 117.77 12.56 5.64 6.34 
10.10 1.22 1.25 2.96 0.18 0.18 241.20 266.80 9.59 5.20 5.55 
16.30 1.19 1.21 1.75 0.21 0.22 346.32 374.68 7.57 4.68 5.02 
24.70 1.16 1.17 1.39 0.23 0.24 488.50 526.50 7.22 4.38 4.66 
39.30 1.14 1.14 0.00 0.27 0.26 690.98 722.64 4.38 4.02 4.17 
57.10 1.11 1.11 0.01 0.24 0.24 954.97 1001.77 4.67 3.97 4.11 
71.80 1.09 1.09 0.00 0.20 0.21 1111.70 1126.10 1.28 3.77 3.94 
92.00 1.10 1.10 0.00 0.24 0.24 1333.96 1355.50 1.59 3.72 3.87 
119.80 1.08 1.08 0.00 0.22 0.25 1604.90 1655.35 3.05 3.68 3.84 
151.00 1.07 1.07 0.00 0.17 0.20 1893.40 1936.68 2.23 3.61 3.67 
 
Conclusions: Data derived from this dosimetric study showed that 
both the MLC systems very well satisfy the RTOG 0915 guidelines in 
terms of CI as well as GI. In-depth analysis showed that there was a 
marginal benefit in terms of both CI as well as GI with HDMLC over 
MMLC in PTV volume less than 4cc. However clinical significance of 
this marginal benefit warrants further investigation in order to find 
out whether these small dosimetric advantages can narrate into 
clinical outcome. Further the institutions who has only 5mm MMLC can 
still do SBRT as the results showed that it can very well satisfy RTOG 
criteria and match HDMLC provided the volume of PTV is greater than 
4cc. 
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Purpose/Objective: A method was developed to automate RT 
treatment planning for Head and Neck (H&N) cancer in order to 
reduce workload and create consistency in the RT treatment planning 
procedure. 
Materials and Methods: For a group of 8 patients (2 oropharynx, 3 
hypopharynx, 3 larynx), we developed scripts to generate treatment 
plans based on manual delineations of the organs at risk (OARs) and 
PTV. In this planning study we focus on VMAT treatment planning for 
H&N patients, where we consider the elective RT in a sequential 
treatment with a prescribed dose of 23 x 2Gy. For treatment planning 
the Pinnacle3 treatment planning system was used, in combination 
with the native scripting language and Python. We generated 6MV dual 
arc (178-182°) VMAT treatment plans, using the Pinnacle3 SmartArc 
optimization module. The automated method consists of a first 
optimization round using objectives solely on the PTV (Min and Max 
Dose), whole body, brainstem and spinal cord (Max Dose). In a second 
optimization round the objectives for the remaining OARs are 
introduced: base of tongue, constructor muscle, larynx, oral cavity 
and parotid glands. In 5 successive optimization rounds the mean dose 
objectives for these OARs were systematically lowered, by setting an 
objective to reduce the mean dose to the OARs by 1 Gy compared to 
the achieved dose for the latest optimization round, if the score of 
the penalty function was below 10-6. For a fair comparison, all 
treatment plans were automatically prescribed to a PTV coverage of 
V95%=99%. The automatically generated treatment plans (ATPs) were 
evaluated on the dose levels in the OARs, and compared with the 
manually generated clinical treatment plans (CTPs). 
Results: For 6 out of 8 ATPs, the clinical constraints on the OARs (Dmax 
Brainstem, Dmean Base of Tongue, etc … see table) and volume of the 
PTV receiving a high dose (V107%<1%) were met for all ATPs, if they 
were met for the corresponding CTP. In the remaining 2 plans the 
volume of the PTV receiving a high dose was considered unacceptable 
(V107%>>1%) and these plans were not further analyzed. The 
differences in the clinical parameters between the accepted ATP and 
CTP were not significant. These treatment plans are therefore 
considered adequate. This technique can be applied to generate a 
good starting point for clinical treatment plans. However, it remains 
essential that generated ATPs are carefully evaluated by an 
experienced dosimetrist, and that the RT plan is adapted when 
necessary. 
  
 ATP-CTP(sd), Gy) 
Dmax Brainstem -0.4 (2.1) 
Dmean Base of Tongue -0.9 (1.3) 
Dmean Constructor muscle 0.1 (0.8) 
Dmean Larynx 0.3 (0.8) 
Dmean Oral cavity -1.5 (3.6) 
Dmean contralateral parotid gland -0.6 (1.2) 
Dmean ipsilateral parotid gland 1.4 (2.2) 
D1% Spinal cord -0.5 (1.7) 
Table: Average difference in dose levels for OARs in the H&N region 
between the clinical treatment plan (CTP) and automatic treatment 
plan (ATP). The value in parentheses indicates the standard deviation.  
 
Conclusions: Using an automated method for generating VMAT 
treatment plans for H&N cancer, we were able to generate adequate 
treatment plans for 6 out of the 8 considered patients.  
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Purpose/Objective: Lung SBRT has emerged as a promising technique 
to treat early stage lung cancer patients with medically inoperable 
disease and for patients who refuse surgery when using biologically 
effective doses in excess of 100 Gy10. The delivery techniques that 
have been proposed vary in terms of ability to meet treatment 
planning criteria, delivery accuracy and estimated treatment times. 
The purpose of this study is to evaluate coplanar VMAT (C-VMAT), non-
coplanar VMAT (NC-VMAT) and non-coplanar IMRT (NC-IMRT) in terms 
of ability to meet planning criteria, dosimetric accuracy of delivery 
and beam-on time. 
Materials and Methods: There were 18 cases that were identified as 
patients who would have been eligible to enrol on our in-house SBRT 
protocol. Each case had 3 unique treatment plans created: C-VMAT, 
NC-VMAT and NC-IMRT. C-VMAT plans consisted of 2 coplanar 360 
degree arcs. NC-VMAT consisted of a single coplanar 360 degree arc 
and a 90 degree non-coplanar arc created for a couch rotation of 90 
degrees. NC-IMRT consisted of 7 equally spaced co-planar beams and 4 
beams delivered for a couch rotation of 90 degrees. Treatment plans 
were planned with Pinnacle v9 (Philips Medical Systems, Andover, MA, 
USA) and attempted to meet planning goals set out with our in-house 
protocol which was adapted from the British Columbia provincial lung 
SBRT guidelines. All plans were delivered to the ArcCheck device (Sun 
Nuclear Corporation, Melbourne, FL, USA) where both delivery 
accuracy and beam-on time was evaluated. 
Results: Treatment planning criteria can be sub-divided into PTV 
criteria and OAR criteria. For the PTV criteria, all plans were able to 
meet the prescription criteria and high dose spillage criteria however 
the low dose spillage criteria (i.e. ratio of 50% isovolume to PTV) had 
minor deviations for 11/18 C-VMAT plans and 3/18 for both NC-VMAT 
and NC-IMRT plans. For OARs, all plans performed equally well for 
sparing OARs and the inability to meet planning criteria was largely 
due to OAR overlap with the PTV which occurred for ribs in 12/18 
cases, for heart in 3/18 cases and for the great vessels in 2/18 cases. 
The mean lung dose, V20, V10, V5 and V2 were very similar across all 
delivery techniques. The ArcCheck delivery accuracy as evaluated by 
gamma(2%,2 mm) for all 18 cases was 92.6±3.7%for C-VMAT, 
96.6±2.1% for NC-VMAT and 95.1±2.1% for NC-IMRT. The treatment 
times were ~5.0 minutes for C-VMAT, ~7.0 minutes for NC-VMAT and 
~12.5 minutes for NC-IMRT. 
Conclusions: All three treatment techniques were deemed to be 
clinically acceptable by two lung radiation oncologists in terms of plan 
quality, delivery accuracy and treatment times. The main trade-offs 
identified in this study were that C-VMAT produced plans with shorter 
beam-on times while sacrificing conformity for the low dose spillage 
volume.  
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Purpose/Objective: Although helical tomotherapy (HT) is not capable 
of producing noncoplanar beams, its potential to delivery effective 
stereotactic body radiation therapy SBRT treatments has been widely 
demonstrated. Due to the high fraction dose required, HT-based SBRT 
is commonly planned with the narrowest field width (1 cm) and small 
pitch values (approximately 0.1), leading to a significant increase of 
the beam-on time (BOT). HT unit features a flattening filter (FF) free 
6MV photon beam providing an high dose-rate (>800 MU/min) and an 
unflattened dose profile in the lateral direction. The ratios of the off-
axis dose at 5 cm and 10 cm and the maximum dose are 88% and 71%, 
respectively. Thus, the increased dose rate does not directly 
translates into shorter BOTs, since the treatment time results affected 
also by the window of the dose profile involved in the fluence 
modulation. The aim of this work was to investigate the variation of 
the BOT required to deliver a SBRT fraction to a single lung lesion as a 
function of the distance of the PTV from the isocenter (IC) of the 
treatment unit taking also into account the PTV dimensions, assuming 
the volume as an ideal sphere.  
Materials and Methods: 6 patients who previously received SBRT to a 
single-lung lesion were retrospectively replanned repositioning the 
PTV according to the IC of the treatment unit. Plans were redesigned 
keeping the dose constraints unchanged during the optimization and 
DVHs comparison was performed to assess the identity between plans. 
The module of the vector ρ with origin in the IC and lying in the axial 
plane measured the off-axis PTV distance. To account for fraction 
dose and ρ variability, the normalized coefficient ΔBOTnorm was 
introduced to quantify the BOT reduction: 
 
  
where ΔBOT is the BOT difference between the two plans. 
Differences in fraction doses, PTV off-axis positions and diameters (∅) 
are reported in Table 1. 
Results: Deviations between DVHs were all within the 1% in terms of 
both dose and volume difference. A mean reduction in gantry period 
of 3.8s (range 2s – 5s) was observed yielding a ΔBOT mean value of 
116.7s (range 73.8s – 143.1s).  
The ΔBOTnorm mean value was 1.78s/Gy·cm (range 1.4 s/Gy·cm – 2.2 
s/Gy·cm). ΔBOTnorm showed to vary linearly (R2 = 0.999) with ∅ as 
plotted in Figure 1. Higher ΔBOTnorm values were observed for 
sinograms with low fluence contribution by the inner leaves. The 
overall results for each patient are reported in Table 1. 
 
Table 1. 
  
Figure 1. 
  
Conclusions: BOT value required for HT-based SBRT treatments 
resulted to be affected by the PTV distance from IC. The increase of 
the mean fluence intensity yielded by moving the PTV towards the IC 
allows the increase of the gantry speed, thus reducing the overall 
BOT. BOT reduction increased linearly with PTV volume. For the 6 
patients involved, the study showed the potential to decrease the BOT 
up to a factor of 17% which may be considered noticeable with regard 
to the typical range (10 min to 25 min) involved for such treatments. 
Further studies will be focused on the ΔBOTnorm variation as a 
function of the fluence modulation. 
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Purpose/Objective: In stereotactic body radiotherapy (SBRT), the 
positional stability of the target is important to reduce the risk of a 
geographic miss. It has been suggested that long treatment times may 
be associated with greater changes in intrafraction tumor position, 
which if uncorrected could adversely affect target coverage. High 
dose rate flattening filter free (FFF) beams have recently become 
clinically available and these enable short delivery times, especially 
when combined with volumetric modulated arc therapy. The purpose 
of this study was to evaluate intrafraction target stability position 
during fast, frameless FFF lung SBRT and to report how long this 
treatment takes to deliver. 
Materials and Methods: 140 lung SBRT fractions in 32 patients with 
early stage lung cancer or lung metastasis delivered with FFF 
RapidArc® on a TrueBeam™ accelerator at a maximum dose rate of 
2400 MU/minute were reviewed. Dose-fractionation was risk-adapted, 
taking into account tumor size and critical organs. Fractions without 
post-treatment CBCT, performed without high dose rate delivery and 
with session interruption due to coughing or match uncertainty, were 
excluded from this analysis. After initial positioning using lasers, a 
pre-treatment kilovoltage free-breathing (3D) cone-beam computed 
tomography scan (CBCT) was performed with on-line automatic ± 
manual co-registration of the time-averaged target with the average-
intensity projection of the planning 4DCT. After the couch shift, the 
two treatment arcs were delivered, followed by a post-treatment 
CBCT. The translational corrections for the post-treatment CBCT 
(taking into account any intermediate CBCT scans) represented the 
intrafraction change in position of the time-averaged target (Δ). For 
89% of the fractions, the translational data resolution was 0.1mm. A 
3D vector was calculated for each fraction and time metrics were 
calculated. The relation between Δ and treatment time was 
investigated. 
Results: Mean Δ was -0.7 mm (SD=1.4), -0.7 mm (SD=1.3), and +0.2 
mm (SD=1.2) in vertical, longitudinal and lateral directions, 
respectively, with a mean 3D vector of 2.1 mm (SD=1.2). 52% of 3D 
vectors were <2 mm and 96% <5 mm. Mean time for arc delivery was 
4.4 min (SD=3.4) with mean beam-on 1.9 min (SD=0.4). Mean time 
between first and last CBCT was 11.6 min (6.8- 40.4 min, SD=4.0 min). 
Mean 3D vector for upper (n=16) and mid- or lower third lesions (n=18) 
was 2.0 and 2.2 mm, respectively (p=0.20). No correlation was found 
between the 3D vector and time. The addition of a single 
intermediate CBCT added approximately 7 min to the mean fraction 
